Passage Bio will develop therapies for diseases affecting the central nervous system based on research by James Wilson at Penn, after raising almost $116m in a series A round.
Passage Bio, a US-based company developing treatments for neurological diseases based on research at University of Pennsylvania, has received $115.5m in a series A round that included Lilly Asia Ventures, an investment vehicle for pharmaceutical firm Eli Lilly.
The round was led by OrbiMed and included fellow healthcare investment firm Vivo Capital as well as venture capital firms Frazier Healthcare Partners, Versant Ventures and New Leaf Venture Partners.
Passage Bio is developing five drug candidates that are intended to treat diseases affecting the central nervous system (CNS).
The company has signed a research, collaboration and license agreement with the University of Pennsylvania, its Gene Therapy Program and the Penn Orphan Disease Center with the support of Passage Bio co-founder and chief scientific adviser James Wilson, professor in the Perelman School of Medicine.
The company’s lead programs included a treatment for GM1 gangliosidosis, a disease caused when…
